Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Caesarean delivery under general anaesthesia (GA) carries nowadays still 25% risk of insufficient depth of anaesthesia in a time before the fetus delivery. The reason is the lack of opioid administration. Opioids easily cross placental barrier and negatively influence newborn postpartum adaptation by respiratory depression. Introduction to GA is thus accompanied by exaggerated autonomic stress reaction with hypertension and tachycardia. The use of ultra-short acting opioid remifentanil should suppress stress response in mother without increasing the risk for newborn. There are only a few clinical data available. This study will be the first one systematically studying the influence of remifentanil in pregnant women with hypertension on hemodynamic stability and newborns safety. This study will also identify potential pharmacogenetic factors of individual variability in remifentanil response with respect of drug efficacy and safety in mother and newborn.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charles University, Czech Republic
• Collaborator: General Teaching Hospital, Prague
• Treatments: Anesthetics; Remifentanil

Criteria

Inclusion Criteria:

• Pregnant women,

• age 18-45

• Cesarean delivery under general anesthesia

• informed consent

Exclusion Criteria:

• non-cooperative patient

• previous allergy to remifentanil or additional substance

• multiparity

• age of foetus <35th week

• estimated foetus weight <2500 g

• hypoxia or other signs of foetus distress

• mother's hypotension

Discontinuation Criteria:

• difficult foetus delivery (uterine incision-to-delivery interval >3 min)